RegulatoryOfficial
AIFA: Emend 125 mg + 80 mg capsules to leave Italian market on 30 November
🇮🇹 AIFA · Mon 16 Nov 2026
MSD Italia says Merck Sharp & Dohme is permanently ending EU/EEA marketing of Emend (aprepitant) for commercial reasons, not because of safety, efficacy or quality concerns.
The Italian Medicines Agency (AIFA) announced on 16 November 2026 that Emend (aprepitant) will be permanently withdrawn from sale. MSD Italia S.r.l., the local representative of Merck Sharp & Dohme B.V., told AIFA and other European regulators that marketing will cease across the European Union and European Economic Area.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Article written by VigiEye from the official source (AIFA). AI-assisted; check the source before acting.
More Regulatory
All →
Galectin files belapectin Phase 3 protocol with FDA as chairman converts $105.8M debt
🇺🇸 Galectin Therapeutics Inc (GALT) · Mon 16 Nov 2026
Apnimed's sleep apnoea drug AD109 awaits FDA decision with 28 February 2027 goal date
🇺🇸 Apnimed, Inc. (APMD) · Mon 16 Nov 2026
FDA sets 25 March 2027 goal date for Unicycive's resubmitted oxylanthanum carbonate application
🇺🇸 Unicycive Therapeutics, Inc. (UNCY) · Mon 16 Nov 2026
FDA grants orphan drug designation to Noema's basimglurant for trigeminal neuralgia
Noema Pharma AG · Mon 16 Nov 2026
FDA issues complete response letter for Summit's ivonescimab in EGFR-mutant NSCLC
🇺🇸 Summit Therapeutics Inc. (SMMT) · Mon 16 Nov 2026
Invivyd Q3 Pemgarda revenue reaches $15.4M as VYD2311 data timing shifts after FDA talks
🇺🇸 Invivyd, Inc. (IVVD) · Mon 16 Nov 2026